Table 1.
Patient Characteristics
| T/E cohort (n = 22) |
Control cohort (n = 17) |
P-value | |
|---|---|---|---|
| Age at therapy onset | .74 | ||
| ≥55 years | 14 (64%) | 12 (71%) | |
| <55 years | 8 (36%) | 5 (29%) | |
| KPS at therapy onset, n | .46 | ||
| ≥90% | 7 (32%) | 3 (18%) | |
| <90% | 15 (68%) | 14 (82%) | |
| Sex, n | .74 | ||
| Men | 12 (55%) | 11 (65%) | |
| Women | 10 (45%) | 6 (35%) | |
| MGMT promoter status, n | .74 | ||
| Methylated | 7 (32%) | 7 (41%) | |
| Unmethylated | 15 (68%) | 10 (59%) | |
| Investigated treatment line, n | .73 | ||
| ≥2. recurrence | 16 (73%) | 11 (65%) | |
| 1. recurrence | 6 (27%) | 6 (35%) | |
| Additional treatment in investigated therapy line, n | .73 | ||
| Radiotherapy | 2 (9%) | 2 (12%) | |
| Surgery | 6 (27%) | 3 (18%) | |
| TTFields | 5 (23%) | 6 (35%) | |
| None | 12 (55%) | 7 (41%) | |
| Time from initial glioblastoma diagnosis to start of investigated therapy in months, range (median) | 5–57 (16) | 5–79 (11) | .63 |
| Time from baseline MRI to therapy onset in days, range (median) | 1–30 (16) | 6–30 (21) | .62 |
| Investigated therapy time in weeks, range (median) | 8–64 (12) | 6–22 (8) | .01 |
| Follow-up in months, range (median) | 3–41 (9) | 3–11 (6) | <.01 |
KPS, Karnofsky performance score; MGMT, 06-methylguanine-DNA methyltransferase; MRI, magnetic resonance imaging; T/E, combination of trofosfamide with etoposide; TTFields, tumor treating fields.